Iovance Biotherapeutics Inc to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer- Conference Call Transcript
Thank you for standing by, and welcome to the Iovance Biotherapeutics update call. (Operator Instructions)
Please be advised that today's conference may be recorded. (Operator Instructions)
I would now like to hand the conference over to your host, Sara Pellegrino. Please go ahead.
Thank you. Good afternoon, and thank you for joining our conference call to discuss the initial clinical data for our TIL cell therapy LN-145 in metastatic non-small cell lung cancer, or NSCLC.
For today's agenda, our Interim President and CEO, Fred Vogt, will do a brief introduction; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Dr. Madan Jagasia, our Senior Vice President, Medical Affairs, will then highlight the clinical data, and we will hold a question-and-answer session.
Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's clinical results,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
